Articles On Race Oncology (ASX:RAC)

Race Oncology (ASX: RAC) has announced the publication of a peer-reviewed preclinical study that has identified additional drug combinations showing synergy with its cancer-fighting drug Zantrene when tested in acute myeloid leukaemia (AML)...

Race Oncology (RAC) announces its lead Zantrene drug has been found to show synergy with several other drug combinations when tested in Acute Myeloid Leukaemia cells Researchers from the MD Anderson Cancer Center in Texas found a number of...

Inoviq (ASX:IIQ) has been granted a Brazilian patent covering the use of BARD1 isoforms in lung and colorectal cancer. Specifically, the patent covers a method for detecting the presence of the specific BARD1 isoforms, and a method for disc...

“This work provides further preclinical data to support our upcoming Phase 1b/2 extramedullary AML trial in Australian and Europe, where patients will be treated with Zantrene in combination with decitabine or cytarabine,” CHM chief scienti...

They say if you can’t measure it, you can’t manage it – and that holds particularly true when it comes to sustainability. While all the talk has been on achieving net zero by 2050, little has been done to address the lack of mandatory repor...

Disclosure: The authors of this article and owners of Next Investors, S3 Consortium Pty Ltd, and associated entities, own 13,631,579 ALA shares. S3 Consortium Pty Ltd has been engaged by ALA to share our commentary on the progress of our in...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

Race Oncology (ASX: RAC) executive director and entrepreneur Dr Daniel Tillett has joined smart energy software as a service company Simble Solutions (ASX: SIS) to help drive commercialisation of its CarbonView and SimbleSense ESG (environm...

The ASX200 has vacillated all of Monday in a whiny, unattractive way for a major global index. Like a Kardashian (name one) unable to get out of bed, the heavyweight financial names and the major miners are just dragging everyone lower, dow...

Christina Manfre, a partner at PKF Sydney, will provide leadership to Race Oncology’s financial analysis, reporting and strategic financial needs.

Race Oncology (RAC) reports $1.8 million in cash outflows for the quarter, an increase from the $931,000 in outflows recorded in the previous quarter The company spent $890,000 during the period for research and development RAC’s focus is...

Key points The Race Oncology share price is up as high as 2.8% today A new discovery relating to heart protection has been made Oversubscribed share purchase plan has raised $29.7 million The Race Oncology Ltd (ASX: RAC) share price is...

Key points Firebrick Pharma will debut on the ASX at 12:30pm AEDT today The company is developing a nasal spray to help treat the common cold. It’s product will also undergo a COVID-19 trial Shares in the company were offered for 20 cents...

“The increased refund for FY21 is representative of the enhanced investment we made into R&D as we expanded our Zantrene clinical and supporting programs," says MD.

Returns in the ASX healthcare basket were fairly robust throughout 2021. Sector earnings saw a return to pre-COVID levels as patient and service volumes began to normalise as well. The S&P/ASX 200 Health Care Index (ASX: XHJ) has clim...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

“The number of applications reflects enthusiasm for the significant potential of our lead drug Zantrene and this enables us to implement our planned clinical and drug development plans across the three-pillar program,” managing director and...

Race Oncology (ASX: RAC) is closing out 2021 with an extra $29.7 million in the bank after completing a heavily oversubscribed share purchase plan that saw almost $44 million in applications. Under the share purchase plan, eligible existing...

Race Oncology (RAC) raises $29.7 million in an oversubscribed share purchase plan The company received applications totalling almost $44 million from 2340 shareholders, with the funds to be used to accelerate the company’s clinical and dev...

The Race Oncology Ltd (ASX: RAC) share price is climbing today on the back of the company’s latest capital raise. During morning trade, the pharmaceutical company’s shares are up 3.64% to $3.42 apiece. What did the company announce? Invest...

After identifying its heart protective effects, Race Oncology (ASX: RAC) has extended the collaboration with the University of Newcastle for its Zantrene (bisantrene dihydrochloride) anti-cancer drug. Earlier this week, Race revealed precli...

This strategically important collaboration will underpin a cardio-protective Phase 2b clinical trial in cancer patients at high risk of anthracycline-induced heart damage, which is expected to begin treating patients in late 2022.

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

Clinical stage RNA focused company targeting multiple cancer indications with estimated annual oncology revenues of >US$2.6 billion

“Zantrene is the first anti-cancer agent that we have found to exhibit a cardioprotective profile while being synergistically effective as an anti-cancer treatment," says University of Newcastle associate professor Doan Ngo.

Specialty pharmaceutical company Race Oncology (ASX: RAC) has found its lead candidate Zantrene (bisantrene dihydrochloride) is able to protect heart muscles from cell death caused by chemotherapy drug carfilzomib. Results from a preclinica...

Race Oncology (RAC) confirms Zantrene can protect heart muscle cells from carfilzomib-induced cell death while improving the carfilzomib-mediated killing of cancer cells Associate Professor Doan Ngo says Zantrene showed it can salvage over...

Precision oncology company Race Oncology (ASX: RAC) is looking to raise capital to enable the execution of its expanded business strategy and to progress the clinical program of its anti-cancer drug Zantrene following a recent breakthrough...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

The ASX drifted sideways on Wednesday, as uncertainty continues to linger around the outlook for monetary policy, interest rates and broader market liquidity following the reappointment of Jerome Powell as US Fed chair. While the ASX 200 tr...

Investors are selling off shares in precision oncology company Race Oncology Ltd (ASX: RAC) after a flurry of market sensitive announcements yesterday. At the time of writing, shares in the RNA focused company are down around 12.47% at $3...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has just dropped into the red. At the time of writing, the benchmark index is down slightly to 7,408.9 points. Four ASX shares that are falling more than most today are listed below....

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Highlights As per experts, the global cancer drug market is likely to accelerate in the upcoming years due to the widespread prevalence of cancer.  The increased focus of the healthcare sector on cancer research has been a critical fac...

The Australian bourse recouped most of yesterday’s losses despite tech stocks dropping again, this time by 3.49%. The ASX 200 rose 0.78%, closing at 7,411 points, with the gains driven by the resources and energy sectors, which gained 2.3%...

Cancer biotech Race Oncology is tapping its base of loyal retail shareholders for a fresh capital raise of up to $30 million,

The company said this is the first time a drug has demonstrated the ability to both target the cancer and protect the heart from anthracycline damage.

Shares in Australian pharmaceutical company Race Oncology Ltd (ASX: RAC) jumped higher today and finished 13% in the green. Investors bid up the Race Oncology share price following study readouts for its lead drug candidate, Zantrene, in...

Race Oncology’s drug Zantrene shown to protect human heart muscle cells from anthracycline-induced chemotherapy death. Anthracycline’s are the most used and effective anti-cancer drugs, yet they can cause serious heart damage. The preclin...

The ASX 200 Health Index (XHJ) is down by 0.35% at the time of writing, compared to the broader index which is down by 0.80%. A private fund owned by the Forrest family, Tattarang, has invested $5m or 7.3% stake in cannabis company, Emyria...

Interim research results has found Race Oncology’s (RAC) Zantrene drug can protect heart muscles from anthracycline induced cell death while boost the killing of breast cancer cells Anthracyclines are one of the most effective anti-cancer...

Race Oncology (RAC) joins forces with the University of Wollongong (UOW) for a preclinical evaluation of new formulations of its Zantrene anti-cancer drug The collaboration provides Race with access to UOW’s lab and expertise to rapidly ad...

The ASX 200 Health Index (XHJ) is up by 0.57% at the time of writing, compared to the broader index which is up by 0.03%. The US FDA has cleared Pharmaxis (ASX:PXS)’s Investigational New Drug application (IND) for a trial of its lead drug,...

Shares in Australian pharmaceutical company Race Oncology Ltd (ASX: RAC) are up 4% from the open to now trade at $3.41 apiece. This follows an intraday high of $3.52. Race Oncology shares are on the move despite there being no market-sensi...

Race Oncology (RAC) reports a slight decrease in cash and equivalents to $8.94 million as of 30 September 2021, down from $9.32 million as of 30 June 2021 The minimal decrease in cash reserves, according to Race, reflects option exercise p...

The Race Oncology Ltd (ASX: RAC) share price is edging lower today despite a positive development by the pharmaceutical company. At the time of writing, Race Oncology shares are fetching for $3.23, down 2.12%. This means over the past mont...